Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients

• Published in: Frontiers in cellular and infection microbiology 2022-03, Vol.12, p.820367-820367
• Main Authors: Ding, Dafa, Yong, Huijuan, You, Na, Lu, Wei, Yang, Xu, Ye, Xiaolong, Wang, Yayun, Cai, Tingting, Zheng, Xiaoling, Chen, Hui, Cui, Bota, Zhang, Faming, Liu, Xingyin, Mao, Jian-Hua, Lu, Yibing, Chang, Hang
• Format: Article
• Language: English
• Subjects: BASIC BIOLOGICAL SCIENCES; Cellular and Infection Microbiology; Diabetes Mellitus, Type 2 - therapy; Fecal Microbiota Transplantation; Feces; Glycated Hemoglobin A; gut microbiome; Humans; prospective cohort study; Prospective Studies; RNA, Ribosomal, 16S - genetics; therapeutic biomarker; Treatment Outcome; type 2 diabetes mellitus
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2022.820367

Increasing evidence shows that alterations in gut microbiome (GM) contribute to the development of type 2 diabetes mellitus (T2DM), and fecal microbiota transplantation (FMT) successfully treats various human diseases. However, the benefits of FMT therapy to T2DM patients remain unknown. We enrolled 17 patients with T2DM for nonblinded, one-armed intervention trial of FMT. A total of 20 healthy individuals were recruited as the baseline control. HbA1c% and metabolic parameter change were evaluated in 17 T2DM patients 12 weeks after they received FMT from healthy donors. The GM composition was characterized by 16S rRNA gene amplicon sequencing from fecal samples prior to and 12 weeks after FMT treatment. We found that the GM of T2DM patients was reconstituted by FMT. We observed a statistically significant decrease in HbA1c% (from 7.565 ± 0.148 to 7.190 ± 0.210, p